8 recruiting. 7 Phase 2, 1 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 7 | Recruiting 7 |
| Phase 1 | 1 | Recruiting 1 |
| Phase 3 | 1 | Recruiting 1 |
Follow Hudson Biotech: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Effect of LY3437943 Versus Placebo in Participants Who Have Obesity or Are Overweight Retatrutide (LY3437943), Placebo, Standardized diet and physical activity counseling throughout the study. - Obesity | Phase 2 | Recruiting | Hudson Biotech | 300 | 2026-02-15 | 2026-03-12 |
| TB-500 (Thymosin Beta 4 17-23 Fragment) for Cardiovascular Biomarkers in Stable ASCVD TB-500, Placebo - Atherosclerotic Cardiovascular Diseases, Endothelial Dysfunction | Phase 1 / Phase 2 | Recruiting | Hudson Biotech | 80 | 2026-02-05 | 2026-03-23 |
| MOTS-c for Improving Insulin Sensitivity in Adults With Prediabetes and Overweight/Obesity MOTS-c (MDP), Placebo, Route Subcutaneous injection - Prediabetes, Insulin Resistance | Phase 2 | Recruiting | Hudson Biotech | 120 | 2026-02-02 | 2026-04-01 |
| Melanotan II (MT-II) as an Adjunct to NB-UVB Phototherapy for Repigmentation in Stable Nonsegmental Vitiligo Melanotan II (MT-II), Placebo, Narrowband UV-B (NB-UVB) phototherapy - NonSegmental Vitiligo, Nonsegmental Vitiligo (Stable) | Phase 2 | Recruiting | Hudson Biotech | 60 | 2026-02-02 | 2026-02-27 |
| Efficacy and Safety of Tirzepatide Once Weekly Versus Placebo in Participants Who Are Either Obese or Overweight With Weight-Related Comorbidities (SURMOUNT-1) Tirzepatide, Placebo, Reduced-calorie diet - Obesity, Overweight (Without Type 2 Diabetes) With Weight-related Comorbidities | Phase 3 | Recruiting | Hudson Biotech | 2539 | 2026-02-02 | 2026-03-19 |
| BPC 157 for Acute Hamstring Muscle Strain Repair Pentadecapeptide BPC 157, Placebo - Hamstring Muscle Strain, Skeletal Muscle Injury | Phase 2 | Recruiting | Hudson Biotech | 120 | 2026-02-02 | 2026-02-27 |
| Topical GHK-Cu Gel for Acute Skin Wound Healing GHK-Cu Gel (Copper(II)-peptide complex), vehicle Gel (placebo comparator) - Acute Standardized Cutaneous Wounds (Punch-biopsy Wounds) | Phase 2 | Recruiting | Hudson Biotech | 60 | 2026-02-02 | 2026-02-27 |
| Tesamorelin for Reduction of Liver Fat in Adults With Fatty Liver Disease (Mock Study) Tesamorelin, Placebo, Standardized lifestyle counseling - Metabolic Associated Steatotic Liver Disease, Nonalcoholic Steatohepatitis | Phase 2 | Recruiting | Hudson Biotech | 120 | 2026-02-02 | 2026-03-19 |
Obesity (3) · Overweight (2) · Atherosclerosis (1) · Body Weight (1) · Fatty Liver (1) · Fibrosis (1) · Inflammation (1) · Insulin Resistance (1) · Metabolic Syndrome (1) · Non-alcoholic Fatty Liver Disease (1) · Pigmentation Disorders (1) · Prediabetic State (1) · Sprains and Strains (1) · Vitiligo (1) · Weight Loss (1)
Clinical Protocols (1) · Phototherapy (1) · Tirzepatide (1) · dipeptidase 1 (1) · melanotan-II (1) · retatrutide (1) · tesamorelin (1)
China (8)